VantAI, a generative AI and protein interaction design company, entered a collaboration with Halda Therapeutics valued over $1 billion to develop novel selective proximity-based therapies across oncology and immunology. The partnership combines VantAI’s Neo-1 model and NeoLink structural proteomics platform with Halda’s RIPTAC drug candidates to identify and validate target-effector pairs for regulated-induced proximity targeting chimeras. VantAI’s approach targets protein interaction dysfunctions, offering broad therapeutic potential beyond surface proteins, expanding treatment possibilities in diseases where conventional modalities fall short.